These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37924928)

  • 1. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
    Guan L; Su W; Zhong J; Qiu L
    Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
    Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
    Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
    Thoren KL
    Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
    Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
    J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.
    Wijnands C; Langerhorst P; Noori S; Keizer-Garritsen J; Wessels HJCT; Gloerich J; Bonifay V; Caillon H; Luider TM; van Gool AJ; Dejoie T; VanDuijn MM; Jacobs JFM
    Clin Chem Lab Med; 2024 Feb; 62(3):540-550. PubMed ID: 37823394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
    Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
    J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum.
    Tapia-Alveal C; Olsen TR; Worgall TS
    Commun Biol; 2020 Dec; 3(1):781. PubMed ID: 33335255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
    Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
    Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
    Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
    Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.
    Broijl A; de Jong ACM; van Duin M; Sonneveld P; Kühnau J; van der Velden VHJ
    Am J Clin Pathol; 2022 Apr; 157(4):494-497. PubMed ID: 34643211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma.
    Muccio S; Hirtz C; Descloux S; Fedeli O; Macé S; Lehmann S; Vialaret J
    Clin Chim Acta; 2024 Jan; 552():117634. PubMed ID: 37980975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bringing mass spectrometry into the care of patients with multiple myeloma.
    Murray DL
    Int J Hematol; 2022 Jun; 115(6):790-798. PubMed ID: 35471500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients.
    Wijnands C; Armony G; Noori S; Gloerich J; Bonifay V; Caillon H; Luider TM; Brehmer S; Pfennig L; Srikumar T; Trede D; Kruppa G; Dejoie T; van Duijn MM; van Gool AJ; Jacobs JFM; Wessels HJCT
    Clin Chem Lab Med; 2024 Nov; 62(12):2507-2518. PubMed ID: 38872409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
    Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
    Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
    Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; Mateos MV; Montes de Oca R; Mukundan L; Munshi NC; O'Donnell EK; Orfao A; Paiva B; Patel R; Pugh TJ; Ramasamy K; Ray J; Roshal M; Ross JA; Sigman CC; Thoren KL; Trudel S; Ulaner G; Valente N; Weiss BM; Zamagni E; Kumar SK
    Clin Cancer Res; 2021 Oct; 27(19):5195-5212. PubMed ID: 34321279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.
    Sedlarikova L; Kubiczkova L; Kryukov F; Pelcova J; Adam Z; Pour L; Hajek R; Sevcikova S
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):554-61. PubMed ID: 24993743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.